Literature DB >> 25939962

Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.

Robert Sheppard Nickel1,2, Marla Daves1, Frank Keller1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25939962     DOI： 10.1002/pbc.25551

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  7 in total

1.  Molecular characterization reveals NF1 deletions and FGFR1-activating mutations in a pediatric spinal oligodendroglioma.

Authors:  Amy K Bruzek; Andrew H Zureick; Paul E McKeever; Hugh J L Garton; Patricia L Robertson; Rajen Mody; Carl J Koschmann
Journal:  Pediatr Blood Cancer       Date:  2016-11-10       Impact factor: 3.167

2.  Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Authors:  Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  Transl Res       Date:  2017-08-10       Impact factor: 7.012

Review 3.  Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.

Authors:  Amy N Sexauer; Sarah K Tasian
Journal:  Front Pediatr       Date:  2017-11-20       Impact factor: 3.418

4.  Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma".

Authors:  Joseph R Linzey; Bernard Marini; Kathryn McFadden; Adonis Lorenzana; Rajen Mody; Patricia L Robertson; Carl Koschmann
Journal:  NPJ Precis Oncol       Date:  2017-09-07

Review 5.  Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.

Authors:  Francesca Carofiglio; Antonio Lopalco; Angela Lopedota; Annalisa Cutrignelli; Orazio Nicolotti; Nunzio Denora; Angela Stefanachi; Francesco Leonetti
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

6.  Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase.

Authors:  Jae Wook Lee; Jae Won Yoo; Seongkoo Kim; Pil-Sang Jang; Nack-Gyun Chung; Bin Cho
Journal:  Blood Res       Date:  2021-12-31

7.  Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib.

Authors:  Diana Corallo; Fabio Pastorino; Marcella Pantile; Elena Mariotto; Federico Caicci; Giampietro Viola; Mirco Ponzoni; Gian Paolo Tonini; Sanja Aveic
Journal:  J Exp Clin Cancer Res       Date:  2020-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.